grant
MDM2-HIF signaling in pathological ventricular remodeling
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 15 Apr 2024Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY202521+ years oldAdultAdult HumanAsymmetric Septal HypertrophyBlood capillariesBody TissuesCardiac Muscle CellsCardiac MyocytesCardiocyteCardiomyopathiesCause of DeathCell BodyCell Communication and SignalingCell CycleCell Division CycleCell SignalingCell divisionCellsChemicalsDNA DamageDNA InjuryDNA ReplicationDNA SynthesisDNA biosynthesisDiastolic heart failureDiseaseDisorderDysfunctionFunctional disorderGene AlterationGene MutationGeneralized GrowthGeneticGenetic DiseasesGenetic ModelsGlycolysisGoalsGrowthHF with preserved ejection fractionHFpEFHIF 1 alphaHIF-1alphaHIF1-AlphaHIF1AHIF1A geneHIF1αHeartHeart Muscle CellsHeart failureHeart myocyteHereditary ventricular hypertrophyHumanHypertrophic CardiomyopathyHypertrophic Obstructive CardiomyopathyHypertrophyIdiopathic Hypertrophic Subvalvular StenosisIdiopathic hypertrophic subaortic stenosisIntermediary MetabolismIntracellular Communication and SignalingLV remodelingLeft Ventricular HypertrophyLeft Ventricular RemodelingMOP1MetabolicMetabolic ProcessesMetabolismMiceMice MammalsModelingModern ManMolecularMurineMusMyocardialMyocardial DiseasesMyocardial DisorderMyocardial depressionMyocardial dysfunctionMyocardiopathiesPathologicPathologic ProcessesPathological ProcessesPathway interactionsPatientsPhysiopathologyPlayPopulationProteinsRoleSarcomeresSecondary toSignal PathwaySignal TransductionSignal Transduction SystemsSignalingTestingTissue GrowthTissuesVentricle RemodelingVentricular Cardiac RemodelingVentricular Myocardial RemodelingVentricular Remodelingadulthoodbiological signal transductioncapillarycardiac dysfunctioncardiac failurecardiomyocytedensitydisease modeldisorder modelexperimentexperimental researchexperimental studyexperimentsgain of functiongene defectgenetic conditiongenetic disorderheart dysfunctionheart failure with preserved ejection fractionheart failure with preserved systolic functionhypertrophic myocardiopathyimprovedinnovateinnovationinnovativeleft ventricle remodelingloss of functionmortalitymouse modelmurine modelmutantmutant allelemyocardial remodelingmyocardium diseasemyocardium disordernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-geneticnongeneticnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyontogenypathophysiologypathwaypostnatalpreserved ejection fraction heart failurepressurepreventpreventingreplication stressresponsesocial role
Description preview
Project Summary:
Multiple acquired and genetic conditions can lead to pathological left ventricular hypertrophy (LVH). It has been
recognized for over 50 years that pathological LVH is associated with increased mortality in the human
population, and it is strongly associated with both heart failure with preserved systolic function (HFpEF) and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click